The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.
Aryl hydrocarbon receptor ligands in cancer: friend and foe
Open accessAbstract
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that is best known for mediating the toxicity and tumour-promoting properties of the carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin, commonly referred to as 'dioxin'. AHR influences the major stages of tumorigenesis — initiation, promotion, progression and metastasis — and physiologically relevant AHR ligands are often formed during disease states or during heightened innate and adaptive immune responses. Interestingly, ligand specificity and affinity vary between rodents and humans. Studies of aggressive tumours and tumour cell lines show increased levels of AHR and constitutive localization of this receptor in the nucleus. This suggests that the AHR is chronically activated in tumours, thus facilitating tumour progression. This Review discusses the role of AHR in tumorigenesis and the potential for therapeutic modulation of its activity in tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Zelante, T., Iannitti, R. G., Cunha, C., De Luca, A., Giovannini, G., Pieraccini, G., Zecchi, R., D’Angelo, C., Massi-Benedetti, C., Fallarino, F., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.003 · Cited by 2,614
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Denison, M. S., & Nagy, S. R. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.135828 · Cited by 1,895
Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., Caccamo, M., Oukka, M., & Weiner, H. L. (2008) · Nature · doi:10.1038/nature06880 · Cited by 1,865
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,601
Poland, A., Glover, E., & Kende, A. S. (1976) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)33205-2 · Cited by 1,370
Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells
Boitano, A. E., Wang, J., Romeo, R., Bouchez, L. C., Parker, A. E., Sutton, S. E., Walker, J. R., Flaveny, C. A., Perdew, G. H., Denison, M. S., et al. (2010) · Science · doi:10.1126/science.1191536 · Cited by 1,047
Self-citation
Cited by
Lactobacillus reuteri induces gut intraepithelial CD4 + CD8αα + T cells
Cervantes-Barragan, L., Chai, J. N., Tianero, M. D., Di Luccia, B., Ahern, P. P., Merriman, J., Cortez, V. S., Caparon, M. G., Donia, M. S., Gilfillan, S., et al. (2017) · Science · doi:10.1126/science.aah5825 · Cited by 896
Hezaveh, K., Shinde, R. S., Klötgen, A., Halaby, M. J., Lamorte, S., Ciudad, M. T., Quevedo, R., Neufeld, L., Liu, Z. Q., Jin, R., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.01.006 · Cited by 746
Gut mucosal microbiome across stages of colorectal carcinogenesis
Nakatsu, G., Li, X., Zhou, H., Sheng, J., Wong, S. H., Wu, W. K. K., Ng, S. C., Tsoi, H., Dong, Y., Zhang, N., et al. (2015) · Nature Communications · doi:10.1038/ncomms9727 · Cited by 701
Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor
Scott, S. A., Fu, J., & Chang, P. V. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000047117 · Cited by 696
Natividad, J. M., Agus, A., Planchais, J., Lamas, B., Jarry, A. C., Martin, R., Michel, M.-L., Chong-Nguyen, C., Roussel, R., Straube, M., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.001 · Cited by 642
“AhR activation leads to several cellular responses and pathways including hormone and immune responses (Furue et al., 2014; Hao and Whitelaw, 2013; Leavy, 2011; Murray et al., 2014; Lamas et al., 2018), and thus can greatly influence health and disease risks.”
BackgroundIndole and Tryptophan Metabolism: Endogenous and Dietary Routes to Ah Receptor Activation
Hubbard, T. D., Murray, I. A., & Perdew, G. H. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.064246 · Cited by 640
Self-citationIL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression
Sadik, A., Somarribas Patterson, L. F., Öztürk, S., Mohapatra, S. R., Panitz, V., Secker, P. F., Pfänder, P., Loth, S., Salem, H., Prentzell, M. T., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.038 · Cited by 559
Liu, Y., Liang, X., Dong, W., Fang, Y., Lv, J., Zhang, T., Fiskesund, R., Xie, J., Liu, J., Yin, X., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.005 · Cited by 535
Aryl hydrocarbon receptor and intestinal immunity
Lamas, B., Natividad, J. M., & Sokol, H. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0019-2 · Cited by 516
Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome
Weinert, B. T., Narita, T., Satpathy, S., Srinivasan, B., Hansen, B. K., Schölz, C., Hamilton, W. B., Zucconi, B. E., Wang, W. W., Liu, W. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.033 · Cited by 509
Vogel, C. F. A., Van Winkle, L. S., Esser, C., & Haarmann-Stemmann, T. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101530 · Cited by 497
Fates of CD8+ T cells in Tumor Microenvironment
Maimela, N. R., Liu, S., & Zhang, Y. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.11.004 · Cited by 459
AHR in the intestinal microenvironment: safeguarding barrier function
Stockinger, B., Shah, K., & Wincent, E. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00430-8 · Cited by 403
Wirthgen, E., Hoeflich, A., Rebl, A., & Günther, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01957 · Cited by 378
IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor
Liu, Y., Zhou, N., Zhou, L., Wang, J., Zhou, Y., Zhang, T., Fang, Y., Deng, J., Gao, Y., Liang, X., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00850-9 · Cited by 372
Structural integration in hypoxia-inducible factors
Wu, D., Potluri, N., Lu, J., Kim, Y., & Rastinejad, F. (2015) · Nature · doi:10.1038/nature14883 · Cited by 346
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
Tang, K., Wu, Y.-H., Song, Y., & Yu, B. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01080-8 · Cited by 365
The Aryl Hydrocarbon Receptor: Connecting Immunity to the Microenvironment
Shinde, R., & McGaha, T. L. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.10.010 · Cited by 329
T cell metabolic fitness in antitumor immunity
Siska, P. J., & Rathmell, J. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.007 · Cited by 312
The therapeutic potential of targeting tryptophan catabolism in cancer
Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0664-6 · Cited by 300
Tryptophan in health and disease
(2020) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2019.08.005 · Cited by 294
Yamada, T., Horimoto, H., Kameyama, T., Hayakawa, S., Yamato, H., Dazai, M., Takada, A., Kida, H., Bott, D., Zhou, A. C., et al. (2016) · Nature Immunology · doi:10.1038/ni.3422 · Cited by 251
Novikov, O., Wang, Z., Stanford, E. A., Parks, A. J., Ramirez-Cardenas, A., Landesman, E., Laklouk, I., Sarita-Reyes, C., Gusenleitner, D., Li, A., et al. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105361 · Cited by 167
Yost, S., Stashenko, P., Choi, Y., Kukuruzinska, M., Genco, C. A., Salama, A., Weinberg, E. O., Kramer, C. D., & Frias-Lopez, J. (2018) · International Journal of Oral Science · doi:10.1038/s41368-018-0037-7 · Cited by 144
Cryo-EM structure of the agonist-bound Hsp90-XAP2-AHR cytosolic complex
Gruszczyk, J., Grandvuillemin, L., Lai-Kee-Him, J., Paloni, M., Savva, C. G., Germain, P., Grimaldi, M., Boulahtouf, A., Kwong, H.-S., Bous, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34773-w · Cited by 137
Grishanova, A. Y., & Perepechaeva, M. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126719 · Cited by 130
Structural characterization of mammalian bHLH-PAS transcription factors
Wu, D., & Rastinejad, F. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.09.011 · Cited by 122
Modeling the binding of diverse ligands within the Ah receptor ligand binding domain
Giani Tagliabue, S., Faber, S. C., Motta, S., Denison, M. S., & Bonati, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-47138-z · Cited by 106
The role of AhR in transcriptional regulation of immune cell development and function
Trikha, P., & Lee, D. A. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188335 · Cited by 96
ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer
Huang, Y.-H., Hu, J., Chen, F., Lecomte, N., Basnet, H., David, C. J., Witkin, M. D., Allen, P. J., Leach, S. D., Hollmann, T. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0529 · Cited by 78
Shi, Z., Lei, H., Chen, G., Yuan, P., Cao, Z., Ser, H.-L., Zhu, X., Wu, F., Liu, C., Dong, M., et al. (2021) · mSystems · doi:10.1128/msystems.00985-20 · Cited by 71
Self-citationStructural basis for the ligand-dependent activation of heterodimeric AHR-ARNT complex
Diao, X., Shang, Q., Guo, M., Huang, Y., Zhang, M., Chen, X., Liang, Y., Sun, X., Zhou, F., Zhuang, J., et al. (2025) · Nature communications · doi:10.1038/s41467-025-56574-7 · Cited by 72
“diseases 6 – 8 .”
Sousa, G., Teixeira, J., Delerue-Matos, C., Sarmento, B., Morais, S., Wang, X., Rodrigues, F., & Oliveira, M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191912677 · Cited by 59
“The metabolism of PAHs causes the activation of AhR and is directly associated with alterations in cell signaling and proliferation, which will promote oxidative stress and thus contribute to the cells’ toxicity and carcinogenicity [66,70].”
BackgroundCryo-EM structure of the cytosolic AhR complex.
Wen, Z., Zhang, Y., Zhang, B., Hang, Y., Xu, L., Chen, Y., Xie, Q., Zhao, Q., Zhang, L., Li, G., et al. (2023) · Structure · doi:10.1016/j.str.2022.12.013 · Cited by 51
Bonati, L., Corrada, D., Giani Tagliabue, S., & Motta, S. (2017) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2017.01.011 · Cited by 27
Corrada, D., Denison, M. S., & Bonati, L. (2017) · Molecular BioSystems · doi:10.1039/c7mb00005g · Cited by 24
In vitro toxicity and in silico docking analysis of two novel selective AH-receptor modulators
Mahiout, S., Tagliabue, S. G., Nasri, A., Omoruyi, I. M., Pettersson, L., Bonati, L., & Pohjanvirta, R. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2018.06.010 · Cited by 19
Faber, S., Lahoti, T., Taylor, E., Lewis, L., Sapiro, J., Toledo Sales, V., Dragan, Y., & Jeffy, B. (2022) · Cells · doi:10.3390/cells11101708 · Cited by 16
Metadata
- Authors
- Murray, I. A., Patterson, A. D., & Perdew, G. H.
- Venue
- Nature Reviews Cancer
- Published
- 2014-11-24
- Volume
- 14
- Issue
- 12
- Pages
- 801-814
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1996613294
- Cited by
- 883
- References
- 169
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.